Anthem Biosciences Limited is set to make its highly anticipated debut on both the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE) on Monday, July 21.
Anthem Biosciences: Ready for Listing
The shares of Anthem Biosciences Limited will officially list on NSE and BSE today, July 21. This follows a successful initial public offering (IPO) that saw significant investor interest last week.
The three-day subscription window for Anthem Biosciences IPO opened on July 14 and closed on July 16. The final allotment for the IPO was completed last week, paving the way for today’s market debut.
Overwhelming Investor Response
The IPO witnessed a remarkable response from investors, being subscribed a staggering 63.86 times by the close of bidding. This indicates strong confidence in the company’s prospects and future growth.
According to data from the NSE, the initial share sale received bids for over 2.81 billion shares, significantly exceeding the 44.07 million shares that were originally on offer. Different investor categories showed varying levels of enthusiasm, contributing to the overall success.
Category-Wise Subscription Details
Qualified Institutional Buyers (QIBs) led the charge with a whopping 182.65 times subscription. This high number suggests robust backing from large financial institutions and professional investors.
Non-institutional investors also showed considerable interest, with their portion being subscribed 42.35 times. Retail individual investors (RIIs) subscribed to their allocated shares 5.64 times, demonstrating solid participation from individual traders and smaller investors.
IPO Key Financials
Anthem Biosciences had fixed its IPO price band between Rs 540 and Rs 570 per equity share. This was the range within which investors could submit their bids during the subscription period.
The face value of each equity share for the IPO was set at Rs 2. Additionally, the tick size, which refers to the minimum price increment for trading the shares, was Re 1.
The Teams Behind the IPO
Several key players facilitated Anthem Biosciences’ journey to the public market. KFin Technologies Limited served as the official registrar for the IPO, managing the crucial application and allotment process for all investors.
The book-running lead managers, responsible for guiding the company through the complexities of the IPO process, included a strong consortium of financial institutions: JM Financial Limited, Citigroup Global Markets India Private Limited, J.P. Morgan India Private Limited, and Nomura Financial Advisory and Securities (India) Private Limited.
HDFC Bank Limited and ICICI Bank Limited acted as the sponsor banks for the IPO, playing a crucial role in the financial aspects and settlement of the offering.
Understanding Anthem Biosciences
Anthem Biosciences Limited operates as an innovation-driven and technology-focused Contract Research, Development, and Manufacturing Organization (CRDMO). Their operations are fully integrated, spanning across drug discovery, development, and manufacturing services.
Beyond contract services, the company also specializes in producing and selling complex, fermentation-based Active Pharmaceutical Ingredients (APIs). Their diverse product portfolio includes a range of specialized items such as probiotics, enzymes, peptides, nutritional actives, vitamin analogues, and biosimilars.
- Anthem Biosciences shares are listing on NSE and BSE on July 21.
- The IPO was oversubscribed 63.86 times in total.
- Qualified Institutional Buyers (QIBs) showed massive interest, subscribing 182.65 times.
- The IPO price band was set between Rs 540 and Rs 570 per share.
- Anthem Biosciences is a CRDMO specializing in drug development and manufacturing of complex APIs.
This listing marks a significant milestone for Anthem Biosciences, opening new avenues for growth and expansion in the competitive pharmaceutical and biotechnology sector.
